RARE250117C80000
- 0.05
- 0.000.00%
Ultragenyx Pharmaceutical Newsroom
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Insider Sale: President & CEO of $RARE (RARE) Sells 11,727 Shares
Ultragenyx Pharmaceutical Insider Sold Shares Worth $495,231, According to a Recent SEC Filing
H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $95
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88
Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
Express News | Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88
NHS England Rolls Out Evkeeza ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older With Homozygous Familial Hypercholesterolaemia (HoFH)
Express News | Ultragenyx Pharmaceutical Inc - Primary Endpoint Is Improvement in Cognition Assessed by Bayley-4
Express News | Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating Gtx-102 in Angelman Syndrome
Express News | Ultragenyx Submits Biologics License Application to the U.S. FDA for Ux111 Aav Gene Therapy for the Treatment of Sanfilippo Syndrome Type a (Mps Iiia)
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Express News | Ultragenyx Pharmaceutical Inc : Jefferies Cuts Target Price to $123 From $124
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)